openPR Logo
Press release

Asthma and COPD Drug Market: Rising Prevalence of Chronic Diseases Driving the Market Growth

07-01-2019 01:36 PM CET | Health & Medicine

Press release from: DataM Intelligence 4Market Research

Asthma and COPD Drug Market: Rising Prevalence of Chronic

The market report titled ‘Global Asthma and COPD Drug Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.

Asthma and COPD Drug Market Drivers
The rising prevalence of chronic diseases is one of the factors fueling global asthma and COPD drug market.
According to the Centers for Disease Control and Prevention (CDC), in 2017, 19.9 million adults aged 18 and over have asthma. About 1 in 12 people have asthma, and the numbers are increasing every year.
According to Asthma UK, 5.4 million people in the UK have asthma, which is 1.1 million children and 4.3 million adults in 2016. In 2016 1,410 people died from asthma. In England, 4,500,000 people (1 in 11) have asthma. This consists of 932,000 children and 3,600,000 adults.
According to the World Health Organization (WHO), More than 65 million people around the world have moderate or severe COPD. The prevalence of COPD increased by 44.2 percent to 174.5 million individuals globally.

Request for a free sample of the report - https://www.datamintelligence.com/research-report/asthma-and-copd-drug-market/

Asthma and COPD Drug Market Size Analysis
Based on drug type, the global market for asthma and COPD drug is broadly segmented as by combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short-acting beta agonists (SABA), long-acting beta agonists (LABA), and others.
In September 2017, GlaxoSmithKline plc and Innoviva, Inc. have received the US Food and Drug Administration (FDA) has approval for single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trilogy Ellipta, with combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in addition treatment of airflow obstruction.

Asthma and COPD Drug Market Regional Analysis
Global asthma and COPD drug market are segmented into North America, Europe, Asia Pacific, South America, and ROW.
North America is dominating global asthma and COPD drug market, due to the regulatory approval and expansion of product portfolio by adding asthma and COPD drug, which is fueling the market growth.
In October 2018, Regeneron Pharmaceuticals, Inc. and Sanofi, have received the U.S. Food and Drug Administration approval for Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

Asthma and COPD Drug Market Competitive Landscape
The strategic alliance between companies and regulatory approval for asthma and COPD drug is one of the critical factor driving global asthma and COPD drug market.
For instance, in December 2018, Teva Pharmaceutical Industries Ltd. have received the U.S. Food and Drug Administration (FDA) approval for ProAir Digital (albuterol sulfate 117 mcg) inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD.
In September 2017, Pulmatrix, Inc. partnered with Vectura Group plc to develop Pulmatrix’s drug, PUR0200, for chronic obstructive pulmonary disease (COPD) for the U.S. market.

Read more information about the research report - https://www.datamintelligence.com/research-report/asthma-and-copd-drug-market/
Table of contents overview -
1. Asthma and COPD Drug Market Scope and Methodology
2. Asthma and COPD Drug Industry Trends
3. Asthma and COPD Drug Market Outlook
4. Market Segmentation Analysis
4.1. BY DRUG TYPE
5. Regional, Country-level Analysis
5.1. Geographic Overview
5.2. North America
5.3. Europe
5.4. South America
5.5. Asia Pacific
5.6. Rest of World
6. Competitive Analysis
7. Company Profiles
8. Key companies to watch
9. Emerging Companies
10. Appendix

Corporate Address
1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

Market Research for long has been losing its credibility owing to low reliability and high proportions of estimations. Having identified this gap, DataM was established to provide businesses with reliable and near-market intelligence. This approach not only aligns the findings with historical data but also allows a highly justifiable forecast model.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Asthma and COPD Drug Market: Rising Prevalence of Chronic Diseases Driving the Market Growth here

News-ID: 1792659 • Views:

More Releases from DataM Intelligence 4Market Research

Ear Infection Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)
Ear Infection Treatment Market Size, Share, Industry, Forecast and outlook (2024 …
Global Ear Infection Treatment Market Poised for Growth, Predicted to Reach USD 16.3 Billion by 2031 The Global Ear Infection Treatment Market, which achieved a milestone of USD 11.3 billion in 2022, is anticipated to experience significant expansion, aiming to surpass USD 16.3 billion by 2031. According to forecasts spanning from 2024 to 2031, the market is set to demonstrate a robust Compound Annual Growth Rate (CAGR) of 4.8%. The ear infection
Neglected Tropical Disease Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)
Neglected Tropical Disease Treatment Market Size, Share, Industry, Forecast and …
Global Neglected Tropical Disease Treatment Market Poised for 5.2% CAGR Growth by 2031 The Neglected Tropical Disease Treatment Market is anticipated to witness significant growth with a projected Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period spanning from 2024 to 2031. Neglected Tropical Diseases (NTDs), a group of approximately 20 diseases primarily prevalent in tropical regions, continue to disproportionately affect impoverished communities, women, and children. Despite the availability of
Drug Discovery Informatics Market Size, Share, Industry, Forecast and outlook (2024-2031)
Drug Discovery Informatics Market Size, Share, Industry, Forecast and outlook (2 …
Global Drug Discovery Informatics Market Expected to Flourish with High CAGR During 2024-2031 Forecast Period The global drug discovery informatics market is anticipated to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2024 to 2031. Drug discovery informatics, a sophisticated system essential for generating extensive information and data, plays a pivotal role in medical research. Medical scientists generate vast amounts of data during the
Ranitidine Market Size, Share, Industry, Forecast and outlook (2024-2031)
Ranitidine Market Size, Share, Industry, Forecast and outlook (2024-2031)
Rapid Growth Projected for Ranitidine Market with High CAGR Expected by 2031 The global Ranitidine Market is anticipated to witness robust growth, exhibiting a high Compound Annual Growth Rate (CAGR) throughout the forecast period from 2024 to 2031. Ranitidine, a member of the histamine-2 blockers group, is poised to address various gastrointestinal conditions effectively. Ranitidine operates by diminishing the production of stomach acid, serving as a vital treatment for ulcers in the

All 5 Releases


More Releases for COPD

Copd CBD Gummies: Reviews (Shocking Facts) Copd CBD Oil "Ingredients" Pain Relie …
Copd CBD Gummies: With the increasing need for both individual and expert degrees, the stress and also stress are also enhancing. Individuals are using various methods to fight it. However, as a result of much less time for self, it is really hard. Here the natural herbs and supplements have actually discovered their way into our lives. The Copd CBD Oil are instances of super-effective natural supplements. The CBD existing
Power Harmonica to Cure Chronic Asthma & COPD
Power Harmonica is a free reed wind musical instrument. It is small rectangular shaped musical instrument. It has 48 number of holes which makes it special and different from other harmonica's. It's a pocket-friendly musical instrument. Power Harmonica is used as a natural treatment for many types of lung disorders and has no side effects. To play Power Harmonica there is no need of having a musical background it can be
COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/copd-therapeutics-market/80858 The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the
04-10-2017 | Health & Medicine
TMR
Asthma and COPD Drugs Market: High Costs of Asthma and COPD Drugs and Consumer A …
Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell that vary in severity and frequency. COPD is a disease of the lungs characterized by obstruction to airflow that interferes with normal breathing. According to the WHO, COPD accounted for over 3 million deaths in 2012, which is equal to 6% of all deaths globally in that year. Moreover, the